Retreatment with erlotinib of a patient with metastatic NSCLC harboring EGFR mutation: a case report
Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor used for the treatment of advanced stage non-small cell lung cancer (NSCLC). Clinical trials have shown high efficacy of erlotinib, particularly in patients harboring activating mutations in the EGFR gene. Here we desc...
Gespeichert in:
| Veröffentlicht in: | Tumori 2014-05, Vol.100 (3), p.e70-e73 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e73 |
|---|---|
| container_issue | 3 |
| container_start_page | e70 |
| container_title | Tumori |
| container_volume | 100 |
| creator | Fiala, Ondrej Pesek, Milos Finek, Jindrich Krakorova, Gabriela Benesova, Lucie Minarik, Marek |
| description | Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor used for the treatment of advanced stage non-small cell lung cancer (NSCLC). Clinical trials have shown high efficacy of erlotinib, particularly in patients harboring activating mutations in the EGFR gene. Here we describe the case of a 42-year-old female light smoker diagnosed with EGFR mutation-positive adenocarcinoma of the left lung with pleural metastases, pleural effusion and metastases to the thoracic vertebrae (stage IV, T4NXM1). Although the patient developed resistance to erlotinib in the first line, she achieved disease stabilization lasting for 13 months as a response to erlotinib retreatment after 6 cycles of second-line chemotherapy. In conclusion, retreatment with erlotinib in our patient was effective. Therefore it should be considered as a good treatment option for patients with NSCLC harboring EGFR mutation. |
| doi_str_mv | 10.1700/1578.17234 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1551021236</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1551021236</sourcerecordid><originalsourceid>FETCH-LOGICAL-p126t-80b49d7a8df1f4e15344e7a184563ed8329109b3e09b3c228f342ac223b5663b3</originalsourceid><addsrcrecordid>eNo9kM1OwzAQhC0kREvhwgMgH7kE_B-HG4raglSBVOAc2cmGBiVxsB2hvj2pKFx2RvPN7mERuqLklqaE3FGZ6skxLk7QnBGuEyZZNkPnIXwSIghT6gzNmCSpYlLMUbWF6MHEDvqIv5u4w-BbF5u-sdjV2ODBxOafdRBNiFNS4ufXfJPjnfHW-ab_wMv1aou78QBdfz8tliYA9jA4Hy_QaW3aAJdHXaD31fItf0w2L-un_GGTDJSpmGhiRValRlc1rQVQyYWA1FAtpOJQac4ySjLL4TBKxnTNBTOT4VYqxS1foJvfu4N3XyOEWHRNKKFtTQ9uDAWVkhJGGVdT9fpYHW0HVTH4pjN-X_x9hv8AlRlhQQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1551021236</pqid></control><display><type>article</type><title>Retreatment with erlotinib of a patient with metastatic NSCLC harboring EGFR mutation: a case report</title><source>SAGE Complete A-Z List</source><source>MEDLINE</source><creator>Fiala, Ondrej ; Pesek, Milos ; Finek, Jindrich ; Krakorova, Gabriela ; Benesova, Lucie ; Minarik, Marek</creator><creatorcontrib>Fiala, Ondrej ; Pesek, Milos ; Finek, Jindrich ; Krakorova, Gabriela ; Benesova, Lucie ; Minarik, Marek</creatorcontrib><description>Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor used for the treatment of advanced stage non-small cell lung cancer (NSCLC). Clinical trials have shown high efficacy of erlotinib, particularly in patients harboring activating mutations in the EGFR gene. Here we describe the case of a 42-year-old female light smoker diagnosed with EGFR mutation-positive adenocarcinoma of the left lung with pleural metastases, pleural effusion and metastases to the thoracic vertebrae (stage IV, T4NXM1). Although the patient developed resistance to erlotinib in the first line, she achieved disease stabilization lasting for 13 months as a response to erlotinib retreatment after 6 cycles of second-line chemotherapy. In conclusion, retreatment with erlotinib in our patient was effective. Therefore it should be considered as a good treatment option for patients with NSCLC harboring EGFR mutation.</description><identifier>EISSN: 2038-2529</identifier><identifier>DOI: 10.1700/1578.17234</identifier><identifier>PMID: 25076254</identifier><language>eng</language><publisher>United States</publisher><subject>Adenocarcinoma - drug therapy ; Adenocarcinoma - genetics ; Adenocarcinoma - pathology ; Adenocarcinoma of Lung ; Adult ; Antineoplastic Agents - therapeutic use ; Bone Neoplasms - secondary ; ErbB Receptors - antagonists & inhibitors ; ErbB Receptors - genetics ; ErbB Receptors - metabolism ; Erlotinib Hydrochloride ; Female ; Humans ; Lung Neoplasms - drug therapy ; Lung Neoplasms - genetics ; Lung Neoplasms - pathology ; Mutation ; Pleural Effusion, Malignant - etiology ; Pleural Neoplasms - secondary ; Positron-Emission Tomography ; Protein Kinase Inhibitors - therapeutic use ; Quinazolines - therapeutic use ; Retreatment ; Thoracic Vertebrae ; Tomography, X-Ray Computed ; Treatment Outcome</subject><ispartof>Tumori, 2014-05, Vol.100 (3), p.e70-e73</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25076254$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fiala, Ondrej</creatorcontrib><creatorcontrib>Pesek, Milos</creatorcontrib><creatorcontrib>Finek, Jindrich</creatorcontrib><creatorcontrib>Krakorova, Gabriela</creatorcontrib><creatorcontrib>Benesova, Lucie</creatorcontrib><creatorcontrib>Minarik, Marek</creatorcontrib><title>Retreatment with erlotinib of a patient with metastatic NSCLC harboring EGFR mutation: a case report</title><title>Tumori</title><addtitle>Tumori</addtitle><description>Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor used for the treatment of advanced stage non-small cell lung cancer (NSCLC). Clinical trials have shown high efficacy of erlotinib, particularly in patients harboring activating mutations in the EGFR gene. Here we describe the case of a 42-year-old female light smoker diagnosed with EGFR mutation-positive adenocarcinoma of the left lung with pleural metastases, pleural effusion and metastases to the thoracic vertebrae (stage IV, T4NXM1). Although the patient developed resistance to erlotinib in the first line, she achieved disease stabilization lasting for 13 months as a response to erlotinib retreatment after 6 cycles of second-line chemotherapy. In conclusion, retreatment with erlotinib in our patient was effective. Therefore it should be considered as a good treatment option for patients with NSCLC harboring EGFR mutation.</description><subject>Adenocarcinoma - drug therapy</subject><subject>Adenocarcinoma - genetics</subject><subject>Adenocarcinoma - pathology</subject><subject>Adenocarcinoma of Lung</subject><subject>Adult</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Bone Neoplasms - secondary</subject><subject>ErbB Receptors - antagonists & inhibitors</subject><subject>ErbB Receptors - genetics</subject><subject>ErbB Receptors - metabolism</subject><subject>Erlotinib Hydrochloride</subject><subject>Female</subject><subject>Humans</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - genetics</subject><subject>Lung Neoplasms - pathology</subject><subject>Mutation</subject><subject>Pleural Effusion, Malignant - etiology</subject><subject>Pleural Neoplasms - secondary</subject><subject>Positron-Emission Tomography</subject><subject>Protein Kinase Inhibitors - therapeutic use</subject><subject>Quinazolines - therapeutic use</subject><subject>Retreatment</subject><subject>Thoracic Vertebrae</subject><subject>Tomography, X-Ray Computed</subject><subject>Treatment Outcome</subject><issn>2038-2529</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kM1OwzAQhC0kREvhwgMgH7kE_B-HG4raglSBVOAc2cmGBiVxsB2hvj2pKFx2RvPN7mERuqLklqaE3FGZ6skxLk7QnBGuEyZZNkPnIXwSIghT6gzNmCSpYlLMUbWF6MHEDvqIv5u4w-BbF5u-sdjV2ODBxOafdRBNiFNS4ufXfJPjnfHW-ab_wMv1aou78QBdfz8tliYA9jA4Hy_QaW3aAJdHXaD31fItf0w2L-un_GGTDJSpmGhiRValRlc1rQVQyYWA1FAtpOJQac4ySjLL4TBKxnTNBTOT4VYqxS1foJvfu4N3XyOEWHRNKKFtTQ9uDAWVkhJGGVdT9fpYHW0HVTH4pjN-X_x9hv8AlRlhQQ</recordid><startdate>201405</startdate><enddate>201405</enddate><creator>Fiala, Ondrej</creator><creator>Pesek, Milos</creator><creator>Finek, Jindrich</creator><creator>Krakorova, Gabriela</creator><creator>Benesova, Lucie</creator><creator>Minarik, Marek</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>201405</creationdate><title>Retreatment with erlotinib of a patient with metastatic NSCLC harboring EGFR mutation: a case report</title><author>Fiala, Ondrej ; Pesek, Milos ; Finek, Jindrich ; Krakorova, Gabriela ; Benesova, Lucie ; Minarik, Marek</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p126t-80b49d7a8df1f4e15344e7a184563ed8329109b3e09b3c228f342ac223b5663b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adenocarcinoma - drug therapy</topic><topic>Adenocarcinoma - genetics</topic><topic>Adenocarcinoma - pathology</topic><topic>Adenocarcinoma of Lung</topic><topic>Adult</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Bone Neoplasms - secondary</topic><topic>ErbB Receptors - antagonists & inhibitors</topic><topic>ErbB Receptors - genetics</topic><topic>ErbB Receptors - metabolism</topic><topic>Erlotinib Hydrochloride</topic><topic>Female</topic><topic>Humans</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - genetics</topic><topic>Lung Neoplasms - pathology</topic><topic>Mutation</topic><topic>Pleural Effusion, Malignant - etiology</topic><topic>Pleural Neoplasms - secondary</topic><topic>Positron-Emission Tomography</topic><topic>Protein Kinase Inhibitors - therapeutic use</topic><topic>Quinazolines - therapeutic use</topic><topic>Retreatment</topic><topic>Thoracic Vertebrae</topic><topic>Tomography, X-Ray Computed</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fiala, Ondrej</creatorcontrib><creatorcontrib>Pesek, Milos</creatorcontrib><creatorcontrib>Finek, Jindrich</creatorcontrib><creatorcontrib>Krakorova, Gabriela</creatorcontrib><creatorcontrib>Benesova, Lucie</creatorcontrib><creatorcontrib>Minarik, Marek</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Tumori</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fiala, Ondrej</au><au>Pesek, Milos</au><au>Finek, Jindrich</au><au>Krakorova, Gabriela</au><au>Benesova, Lucie</au><au>Minarik, Marek</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Retreatment with erlotinib of a patient with metastatic NSCLC harboring EGFR mutation: a case report</atitle><jtitle>Tumori</jtitle><addtitle>Tumori</addtitle><date>2014-05</date><risdate>2014</risdate><volume>100</volume><issue>3</issue><spage>e70</spage><epage>e73</epage><pages>e70-e73</pages><eissn>2038-2529</eissn><abstract>Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor used for the treatment of advanced stage non-small cell lung cancer (NSCLC). Clinical trials have shown high efficacy of erlotinib, particularly in patients harboring activating mutations in the EGFR gene. Here we describe the case of a 42-year-old female light smoker diagnosed with EGFR mutation-positive adenocarcinoma of the left lung with pleural metastases, pleural effusion and metastases to the thoracic vertebrae (stage IV, T4NXM1). Although the patient developed resistance to erlotinib in the first line, she achieved disease stabilization lasting for 13 months as a response to erlotinib retreatment after 6 cycles of second-line chemotherapy. In conclusion, retreatment with erlotinib in our patient was effective. Therefore it should be considered as a good treatment option for patients with NSCLC harboring EGFR mutation.</abstract><cop>United States</cop><pmid>25076254</pmid><doi>10.1700/1578.17234</doi></addata></record> |
| fulltext | fulltext |
| identifier | EISSN: 2038-2529 |
| ispartof | Tumori, 2014-05, Vol.100 (3), p.e70-e73 |
| issn | 2038-2529 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1551021236 |
| source | SAGE Complete A-Z List; MEDLINE |
| subjects | Adenocarcinoma - drug therapy Adenocarcinoma - genetics Adenocarcinoma - pathology Adenocarcinoma of Lung Adult Antineoplastic Agents - therapeutic use Bone Neoplasms - secondary ErbB Receptors - antagonists & inhibitors ErbB Receptors - genetics ErbB Receptors - metabolism Erlotinib Hydrochloride Female Humans Lung Neoplasms - drug therapy Lung Neoplasms - genetics Lung Neoplasms - pathology Mutation Pleural Effusion, Malignant - etiology Pleural Neoplasms - secondary Positron-Emission Tomography Protein Kinase Inhibitors - therapeutic use Quinazolines - therapeutic use Retreatment Thoracic Vertebrae Tomography, X-Ray Computed Treatment Outcome |
| title | Retreatment with erlotinib of a patient with metastatic NSCLC harboring EGFR mutation: a case report |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T00%3A19%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Retreatment%20with%20erlotinib%20of%20a%20patient%20with%20metastatic%20NSCLC%20harboring%20EGFR%20mutation:%20a%20case%20report&rft.jtitle=Tumori&rft.au=Fiala,%20Ondrej&rft.date=2014-05&rft.volume=100&rft.issue=3&rft.spage=e70&rft.epage=e73&rft.pages=e70-e73&rft.eissn=2038-2529&rft_id=info:doi/10.1700/1578.17234&rft_dat=%3Cproquest_pubme%3E1551021236%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1551021236&rft_id=info:pmid/25076254&rfr_iscdi=true |